




Ain Shams University
The Egyptian Journal of Medical Human Genetics

www.ejmhg.eg.net
www.sciencedirect.com



ORIGINAL ARTICLE

Detection of *TET2*, *KRAS* and *CBL* variants by Next Generation Sequencing and analysis of their correlation with *JAK2* and *FLT3* in childhood AML



Dilara Fatma Akin^{a,*}, Deniz Aslar Oner^a, Mine Mumcuoglu^a, Ustun Ezer^b,
Muhterem Bahce^c, Emin Kurekci^b, Nejat Akar^d

^a LOSEV the Foundation for Children with Leukemia, Cancer Genetics Research Laboratory, Ankara, Turkey

^b LOSEV/Losante, The Hospital for Children with Leukemia, Ankara, Turkey

^c Gene-Lab Genetic Diseases Diagnosis Center, Ankara, Turkey

^d TOBB-ETU Hospital, Ankara, Turkey

Received 30 July 2015; accepted 9 September 2015

Available online 1 October 2015

KEYWORDS

Childhood acute myeloid leukemia;
Mutation;
TET2;
KRAS;
CBL;
Next Generation Sequencing

Abstract *Background:* Acute myeloid leukemia (AML) is a heterogeneous clonal disorder in terms of cytogenetic and molecular aberrations. Ten-Eleven-Translocation 2 (*TET2*), Kirsten rat sarcoma viral oncogene homolog (*KRAS*), and Casitas B-cell lymphoma (*CBL*) have an important role pathogenesis of acute myeloid leukemia (AML) and their activated mutations confer proliferative and survival signals.

Aim: In this study, we aimed to find possible genetic markers for molecular analysis in childhood AML by screening hot-spot exons of *TET2*, *KRAS*, and *CBL* using Next Generation Sequencing (NGS) analysis. In addition, association between found variants and mutations of Januse Kinase-2 (*JAK2*) and Fms-Related Tyrosine Kinase (*FLT3*) were analyzed which are important prognostic risk factors for AML.

Methods: Eight patients who were diagnosed with pediatric AML at Losante Pediatric Hematology–Oncology Hospital were included to the study. Hot-spot exons of *TET2*, *KRAS* and *CBL* genes were screened using the NGS method. Furthermore, *FLT3*-Internal Tandem Duplicate (*FLT3-ITD*) and *JAK2*-V617F were analyzed by Real Time Polymerase chain Reaction (Real Time-PCR).

* Corresponding author at: LOSEV Foundation for Children with Leukemia, Cancer Genetics Research Laboratory, Konya – Haymana Yolu, Koparan Koyu Mevkii Golbasi, Incek, Ankara, Turkey. Tel.: +90 5363026816; fax: +90 312 499 43 01.
E-mail address: dilara2684@hotmail.com (D.F. Akin).

Peer review under responsibility of Ain Shams University.

<http://dx.doi.org/10.1016/j.ejmhg.2015.09.002>

1110-8630 © 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Results: In total, we identified 20 variants in studied genes by NGS. In our patient group, 16 variants in the *TET2* (seven novel, seven missense and two silent), two variants in the *KRAS* (one missense and one intronic) and two variants in the *CBL* (two novel) were found. All of AML patients were found negative for JAK V617 F. Three of the eight patients (37.5%) showed mutations of both *FLT3-ITD* and *TET2*, *KRAS*, *CBL*.

Conclusion: We found novel mutations for *TET2*, *KRAS*, and *CBL*. The detected variants in this article seem to be the first screening results of genes studied by NGS in childhood AML patients. Our results also showed some degree of association between *FLT3-ITD* and *TET2*, *KRAS*, *CBL* mutations.

© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

AML is a heterogeneous clonal neoplasm characterized by accumulated genetic aberrations, which causes enhanced proliferation, maturation arrest, increased survival of the leukemic blast cells and variable response to therapy [1–5].

During the past decades, a number of recurrent cytogenetic and molecular genetic abnormalities have been identified in AML such as *t*(8;21), *inv*(16), *FLT3*, *NPM1*, *CEBPA*, *TET2*, *KRAS*, and *CBL*.

TET family gene members (*TET1*, *TET2*, and *TET3*) have functions mostly in hematopoietic differentiation. The TET oncogene family member 2 (*TET2*) gene located at chromosome band 4q24 catalyzes the conversion of 5-methylcytosine to 5-hydroxymethylcytosine [1,6,7]. *TET2* mutations are frequently detected during progression of MPN (myeloproliferative neoplasms) or MDS (myelodysplastic syndromes) to AML [1]. *TET2* mutations may contribute to leukemogenesis by altering epigenetic regulation of transcription via DNA methylation. The incidence of *TET2* mutations is approximately 10–20% in AML [2].

RAS (Rat Sarcoma Virus) proteins including *HRAS* (Harvey Rat Sarcoma Viral Oncogene Homolog), *KRAS* and *NRAS* (Neuroblastoma RAS Viral V-Ras Oncogene Homolog) are members of the small GTPases superfamily [8]. Abnormal RAS function is related to hyperproliferative developmental diseases and cancers [2]. *RAS* mutations, especially *KRAS*, represent about 90% of cancer-associated mutations. *RAS* proteins play a major role in cell signaling pathway of cell proliferation, differentiation, and survival [9]. The *RAS* mutations are the most common mutations in AML which are seen in approximately 25–44% of patients. Among *RAS* mutations, *KRAS* mutations are the most frequently seen and found in 10–15% of these patients [10].

CBL, *CBL-B*, and *CBL C/3* are the members of the *CBL* which is localized on human chromosome 11 q23 containing several functional domains [11]. *CBL* is a mammalian gene encoding the protein CBL which is an E3 ubiquitin-protein ligase involved in cell signaling and protein ubiquitination. Mutations of this gene have been implicated in a number of human cancers, particularly in AML. These mutations have also been observed in 1% of AML. *CBL* mutations have been reported in myeloid malignancies and uniformly affect either the linker region or the RING finger domain. Loss of ubiquitination of activated receptor tyrosine kinases is thought to contribute to the transforming potential of leukemia-associated mutant CBL proteins [12].

JAK2 (located in chromosome 9p24) encodes a cytoplasmic tyrosine kinase. *JAK2V617F* presents a somatic point mutation (including exon 12 of the *JAK2*) resulting in the substitution of valine by phenylalanine amino acid at codon 617. This mutation, which causes JAK homology 2 (JH2) negative regulatory domain, derails *JAK2* kinase regulatory activity which effects cytokine independent proliferation of hematopoietic cells [13]. The *JAK2 V617F* mutation is found in 1.8–28% of patients with AML [14].

FMS-like tyrosine kinase 3 (*FLT3*) is a member of the receptor tyrosine kinase (RTK) III subfamily. The *FLT3* receptor gene (located in chromosome 13q12) encodes a 993 amino acid protein. This protein is expressed in bone marrow, thymus and lymph nodes [15]. *FLT3* plays a major role in cell survival, proliferation, and differentiation of hematopoietic stem cells [16]. *FLT3-ITD* is found in about one quarter of newly diagnosed AML patients. This mutation causes the main activation of the receptor tyrosine kinase activity in the absence of ligand [17].

In our study, we aimed to screen whole *TET2*, *KRAS*, and *CBL* by NGS analysis, evaluating the association of mutations of *JAK2* and *FLT3* which is known as prognostic risk factors and finding possible genetic markers for molecular leukemia analysis. The NGS method is a powerful tool to discover novel disease mutations and candidate biomarkers. Therefore we chose NGS as a screening method for our study.

2. Subjects and methods

2.1. Subjects

The study population consisted of eight patients aged between one and 15 years who were admitted to Losante Hospital for Children with Leukemia with the diagnosis of AML. An informed written consent was obtained from all the patients' parents. Patient characteristics of the eight pediatric AML cases are shown in Table 1.

2.2. Cytogenetic techniques

Bone marrow samples were collected with Heparin-containing tubes, and chromosome analysis was performed using G-banding. After the slide preparation, G-banding using Giemsa-staining was carried out according to the standard procedures. On each slide 20 metaphases were analyzed by a light microscope (Nikon, JAPAN). Karyotypes were described according to ISCN [24].

Table 1 Demographic characteristics and *TET2*, *KRAS*, and *CBL* variants of children with AML.

No	Gender/ age/	Diagnosis	FAB	Risk group	Cytogenetics-Molecular abnormalities	TET2				CBL				KRAS				FLT3 ITD
						Rs number	Nucleotide change	Localization	Amino acid change	Rs number	Nucleotide change	Localization	Amino acid change	Rs number	Nucleotide change	Localization	Amino acid change	
1	M/13	AML	M4	HR	46, XY, monosomy, Trisomy 14	Novel	5284 A > G	Exon 11	Leu- Val	-	-	-	-	-	-	-	-	Negative
2	M/13	AML	M1	HR	t(9;22)	Rs 12498609	86 G > C	Exon 3	Pro- Arg	Rs 17851045	182 A > T	Exon 3	Gln- Leu	-	-	-	-	Negative
3	F/8	AML	M5	SR	46, XX	Rs 17253972 Novel	1088 C > T 1842 G del	Exon 3 Exon 3	Pro- Leu Gly- Gly Ser-Ser	-	-	-	-	Novel	1347 T del	Exon 8	Gly- Gly	Negative
4	F/3	AML + T- ALL	M4	HR	47, XX (+21) c 21 der(14) (14q1,2→q 3,2ii 1q21 → q43),der(19)(19qtel) → p13.3::11q13)11qtel [9]. t(9,22)	Rs 200327850 Rs 112576862 Rs 17253972 Novel	2286 C > T 2386 G > C 1088 C > T 1842 G del	Exon 3 Exon 3 Exon 3	Pro- Leu Ser-Ser Pro- Leu Gly- Gly Ser-Ser	Rs 111836509	310 A > C	Exon 3	Tyr- Stop	Novel	1347 T del	Exon 8	Gly-Gly	Positive
5	M/3	AML	M4	SR	46, XY, monosomy 7	Novel Novel Novel Rs 144386291 Novel	1842 G del 46 A del 730 A del 2599 T > C 5343 A > G	Exon 3 Exon 4 Exon 3 Exon 3 Exon 11	Gly- Gly - - His- Arg His-Val	Rs 111836509	310 A > C	Exon 3	Tyr- Stop	Novel	1347 T del	Exon 8	Gly- Gly	Positive
						Rs 372499795	5164 C > T	3' UTR	Thr-ile									

(continued on next page)

Table 1 (continued)

No	Gender/ age/	Diagnosis	FAB	Risk group	Cytogenetics-Molecular abnormalities	TET2				CBL				KRAS				FLT3 ITD
						Rs number	Nucleotide change	Localization	Amino acid change	Rs number	Nucleotide change	Localization	Amino acid change	Rs number	Nucleotide change	Localization	Amino acid change	
6	M/7	AML	M4	HR	47, XY, + 22[12] Inv (16;16), Fragile X syndrome	Rs 17253972	1088 C > T	Exon 3	Pro-Leu	–	–	–	–	Novel	1347 T del Exon 8	Gly- Gly	Negative	
						Novel	1842 G del	Exon 3	Gly-Gly									
						Rs 142173406	5162 T > G	Exon 11	Leu-Trp									
						Novel	46 A del	Exon 4	–									
						Rs 150298743	100 C > T	Exon 3	Trp-Ile									
						Rs 68431410	652 G > A	Exon 3	Val-Met									
						Novel	5333 A > G	Exon 11	His-Arg									
7	F/9	AML	M2	SR	46, XX	Novel	1842 G del	Exon 3	Gly-Gly	Rs 111836509	310 A > C	Exon 3	Tyr-Stop	Novel	1347 T del Exon 8	Gly- Gly	Negative	
						Novel	46 A del	Exon 4	–									
8	M/8	AML-MDS	M5	HR	46, XX	Rs 12498609	86 G > C	Exon 3	Pro-Arg	–	–	–	–	Novel	1347 T del Exon 8	Gly- Gly	Positive	
						Novel	1842 G del	Exon 3	Gly-Gly									
						Novel	46 A del	Exon 4	–									
														Novel	1111 T > C	Exon 8	Try-His	

HR high risk; SR standard risk; FAB French–American–British classification.

Fluorescence in situ hybridization (FISH) was performed on interphase nuclei and metaphase chromosomes of bone marrow cells using dual-color/dual-fusion probes for translocations of *inv* (16;16), *t*(9;22), *t*(4;14), chromosome 19, and dual-color/deletion probe for *del* 7q, labeled in green and red spectra according to the manufacturer's protocol provided by Cytocell, UK. Counterstaining was performed with 4',6-diamidino-2-phenylindole (DAPI). At least 100 nuclei were analyzed under the Fluorescence microscope, and image capture was performed using Nikon Eclipse 80i equipped with a CCD-camera (CoolCube1), appropriate filters and Isis software (MetaSystems).

2.3. DNA isolation and Next Generation Sequencing

Blood samples were collected with EDTA (Ethylenediaminetetraacetic acid)-containing tubes and DNA was extracted from peripheral blood and bone marrow leukocytes with MagNA Pure automatic DNA isolation instrument (Roche Diagnostics, Mannheim, Germany).

We used NGS to study three candidate genes at *TET2*, *KRAS* and *CBL*. All coding exons of *TET2* (exons 3 and 11) were presented by 27 amplicons. Besides, two primer pairs were amplified known mutational hotspot regions to describe the RING finger domain and linker sequence for *CBL* (exons 8 and 9) and *KRAS* (exons 2 and 3). The analyses were performed as previously described by Kohlmann et al. [18].

Next Generation Sequencing was carried out using 454 GS Junior System Instrument Roche Applied Science. The Data were analyzed using the GS Amplicon Variant Analyzer software version 2.3. (Roche Applied Science, Germany). We used filters which were adjusted to show variants in more than 1% of bidirectional reads per amplicon and per patient to determine the variants.

2.4. Real time PCR

FLT3-ITD and JAK V 617 F mutation were analyzed by Real Time PCR on Light Cycler 480 II instrument (Roche Diagnostics, GmbH, Mannheim, Germany). Results were analyzed with the High Resolution Melting (HRM) method using genotype profiles. Different plots were created by selecting negative controls as the base-line. Therefore, fluorescence of the all other samples was diagramed relative to this sample. Fluorescence signals were analyzed and significant differences used as indicators of mutations [17,19].

3. Results

In this study, we analyzed mutations affecting the *TET2* coding sequence (exons 3–11), *KRAS* (exons 2–3) and *CBL* (exons 8–9) in our patients with pediatric AML. In total, 20 variants were detected by NGS mutation screening method. The results are shown in Table 1. We detected 16 variants in *TET2*, two variants both *KRAS* and *CBL* genes. Table 1 shows the summary of the association of patients' characteristics and variants of *TET2*, *KRAS* and *CBL* profiles.

Karyotype analysis was normal in three of the eight (37.5%) patients. Trisomy 14, Trisomy 19, Trisomy 22, monosomy 7, monosomy 14, *inv* (16;16), *t*(9;22) were found using chromosome banding and FISH analyses. We screened all patients during treatment or relapse. While one patient had 6 *TET2*, 1 *KRAS* gene variants, the other patient had 7 *TET2* variants. Two relapse patients (number 4 and 5) had the same *CBL* variants.

Fig. 1 displays distribution of amplicon reads for patients. The most of *TET2* variants were described in the largest exon 3 and 11; 1842 G > A (6/8 patients, 75%) and 1088 C > T (5/8, 62.5%) variants, 5162 T > G (5/8, 62.5%) in exon 3 and exon




Figure 1 Distribution of generated amplicon sequence reads per patient.

11 of *TET2* gene, respectively. 310 A > C(7/8 87.5%) variation was the highest among the variants in intron 2 of *KRAS* gene. 1347 T > -in exon 8 of *CBL* gene was detected in 6 out 8 patients (75%).

All of AML patients were found negative for JAK V617 F. Three (37.5%) of the eight patients were only FLT3-ITD mutation positive.

4. Discussion

AML is a heterogeneous disorder of hematopoietic stem cells, characterized by multiple genetic events which have an impact on proliferation and differentiation. Some of the genetic and epigenetic alterations play a major role in leukemogenesis; gene mutations, deletions, translocations, and DNA methylation. Recent studies have reported that several genes such as *TET2*, *KRAS*, *CBL*, *FLT3*, *JAK2* involve in the pathogenesis of AML [1,3,6,10,11,18]. Activated *TET2*, *RAS* and *CBL* mutations confer proliferative and survival signals.

In this study, we screened the mutations of *TET2*, *KRAS* and *CBL* genes in childhood AML patients. We used an amplicon based sequencing method to find possible new genetic markers for leukemia diagnosis. *TET2*, *KRAS* and *CBL* genes were selected based on recent studies on genetic abnormalities in AML and other hematologic malignancies. In all patients, we reported novel mutations at *TET2* and *CBL* genes. 7 of 16 substitutions were missense mutations in the exon and UTR (Untranslated region). These mutations may result in truncated translation of protein.

There are very few studies in childhood AML regarding *TET2* mutations. The frequency of *TET2* mutations have been reported to be lower in childhood AML when compared with the adult AML [20]. Coenen et al. have performed PCR and sequencing analyses in order to compare childhood AML with the adult AML. They have shown that the frequency of *CBL* was similar (1–2%). Sano et al. have presented a study using PCR and sequencing analyses and have shown that 29 (18.5%) of the 157 childhood AML patients carried *RAS* mutations [3]. However, *RAS* mutations were reported 25–44% in adult AML [8–10].

In this study, we found 16 variants of which 7 of them are novel. The variants were found to be localized from exon 3 to exon 11 in *TET2* gene (Fig. 2). Metzeler et al. demonstrated that the patients with favorable risk (according to European Leukemia Net (ELN)) and carrying *TET2* mutations had lower response ratios and higher risk of relapse or death when compared to the patients with *TET2* wild type [6]. *TET2*

mutations that have frame shift, nonsense and missense mutations are acquired *JAK2* mutations [2]. Our data suggest that *TET2* variants are more frequent than *CBL* and *KRAS* variants in childhood AML.

Mutant *CBL* affects oncogenic phenotype in different cell lines and induces growth factor independence. Schnittger et al. analyzed 636 patients (MPN/MDS, seconder AML, CMML (Chronic Myelomonocytic Leukemia) and showed several *CBL* mutations localized in LINKER and RING domains in their study group. In addition, the frequency of *CBL* mutations was reported to be higher in patients with mutated *JAK2* V617 F when compared to the patients with *JAK2* V617 wild type [21]. Reindl et al. have detected exons 8 and 9 deletion transcripts of *CBL* in three of 279 AML/MDS patients. In PCR screening of AML/MDS patients, one of 116 patients carried a substitution of arginine to glycine at position 420. In addition, PCR screening revealed loss of the transcripts of mutant *CBL* lacking exons 8 and 9 in remission samples [11].

Several studies have shown that *CBL* promoted down-regulation of *FLT3* activity. Sargin et al. searched the role of c-Cbl in *FLT3* regulation and showed that deregulated *FLT3* activity has significant roles in AML pathogenesis [22]. Reindl et al. revealed that four of 279 AML/MDS patients were found positive for expression of abnormal *CBL* transcripts, and hypothesized that *CBL* mutations might cause the high *FLT3* expression and activation of abnormal *FLT3* [11]. In a previous study, *CBL* variants have been detected at the rate of 1–2% [25]. In our study we also confirmed that AML patients had only two *CBL* variants.

Sano et al. studied 157 pediatric AML patients and reported that *RAS* mutation frequency was higher in AML M4–M5 types than other AML types [3]. Liang et al. searched for mutations in the *RAS* gene in 130 pediatric AML patients. *KRAS* mutation frequency was higher in *MLL* positive AML patients than *MLL* negative AML patients; without statistical significance ($P = 0.069$) [23]. Our screening results showed that seven of the eight patients (87.5%) have the same novel *KRAS* variant (1347 T del), and one patient has two novel variants (1347 T del and 1111 T > C). Relapse patients (number 4 and 5) are showing the same 3 novel *TET2* variants, and same *KRAS* and *CBL* variants. In addition, they present *FLT3*-ITD positivity.

We think that 1347 T del (novel *KRAS* variant) and 1842 G del, 46 A del, 730 A del (3 novel *TET2* variants) could be important prognostic markers for childhood AML/relapse patients and should need further study in a larger group of patient.




Figure 2 Localization of sequence variations in relation to the *TET2* coding sequence.

5. Conclusion

In conclusion, *TET2* mutations are more frequent than *KRAS*, and *CBL* mutations in pediatric AML. In addition, *TET2*, *KRAS*, and *CBL* may potentially be genetic markers for leukemia diagnosis. However, these results need to be confirmed by further studies on a larger number of patients.

Conflict of interest

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

- [1] Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, et al. Landscape of *TET2* mutations in acute myeloid leukemia. *Leukemia* 2012;26:934–42.
- [2] Chan SM, Majeti R. Role of DNMT3A, *TET2*, and *IDH1/2* mutations in pre-leukemic stem cells in acute myeloid leukemia. *Int J Hematol* 2013;98:648–57.
- [3] Sano H, Shimada A, Taki T, Murata C, Park MJ, Sotomatsu M, et al. RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. *Int J Hematol* 2012;5:509–15.
- [4] Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T, et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. *PLoS ONE* 2012;7:e42334.
- [5] Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, et al. Novel oncogenic mutations of *CBL* in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. *J Biol Chem* 2010;285:32596–605.
- [6] Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, et al. *TET2* mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol* 2011;29:1373–81.
- [7] Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, et al. Effects of *TET2* mutations on DNA methylation in chronic myelomonocytic leukemia. *Epigenetics* 2012;7:201–7.
- [8] Zhao S, Zhang Y, Sha K, Tang Q, Yang X, Yu C, et al. *KRAS* (G12D) cooperates with *AML1/ETO* to initiate a mouse model mimicking human acute myeloid leukemia. *Cell Physiol Biochem* 2014;33:78–87.
- [9] Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, et al. Oncogenic *Kras* initiates leukemia in hematopoietic stem cells. *PLoS Biol* 2009;7:e59.
- [10] Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, et al. Conditional expression of oncogenic *K-ras* from its endogenous promoter induces a myeloproliferative disease. *J Clin Invest* 2004;113:528–38.
- [11] Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaut T, Argiropoulos B, et al. *CBL* exon 8/9 mutants activate the *FLT3* pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. *Clin Cancer Res* 2009;15:2238–47.
- [12] Coenen EA, Driessen EM, Zwaan CM, Stary J, Baruchel A, de Haas V, et al. *CBL* mutations do not frequently occur in paediatric acute myeloid leukaemia. *Br J Haematol* 2012;159:577–84.
- [13] Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. *JAK2* exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. *N Engl J Med* 2007;356:459–68.
- [14] Jekarl DW, Han SB, Kim M, Lim J, Oh EJ, Kim Y, et al. *JAK2* V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. *Korean J Hematol* 2010;45:46–50.
- [15] Nasiri N, Shaikhy M, Zaker F, Hosseini S, Moosavi SA, Marjani AJ. Detection and biological characteristic of *FLT3* gene mutations in children with acute leukemia. *Arch Iran Med* 2014;17:258–61.
- [16] Elyamany G, Awad M, Fadalla K, Albalawi M, Al Shahrani M, Al Abdulaaly A. Frequency and prognostic relevance of *FLT3* mutations in Saudi acute myeloid leukemia patients. *Adv Hematol* 2014;14:1360.
- [17] Tan AY, Westerman DA, Carney DA, Seymour JF, Juneja S, Dobrovic A. Detection of *NPM1* exon 12 mutations and *FLT3*-internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia. *J Hematol Oncol* 2008;1:1–10.
- [18] Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in *TET2*, *CBL*, *RAS*, and *RUNX1*. *J Clin Oncol* 2010;28:3858–65.
- [19] Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP, Tubbs RR, et al. Identification of the *JAK2* V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. *Am J Clin Pathol* 2006;125:625–33.
- [20] Langemeijer SM, Jansen JH, Hooijer J, van Hoogen P, Stevens-Linders E, Massop M, et al. *TET2* mutations in childhood leukemia. *Leukemia* 2011;25:189–92.
- [21] Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, et al. Use of *CBL* exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. *Haematologica* 2012;97:1890–4.
- [22] Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff M, et al. *Flt3*-dependent transformation by inactivating *c-Cbl* mutations in AML. *Blood* 2007;110:1004–12.
- [23] Liang DC, Shih LY, Fu JF, Li HY, Wang HI, Hung IJ, et al. *K-Ras* mutations and *N-Ras* mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. *Cancer* 2006;106:950–6.
- [24] ISCN. An International System for Human Cytogenetic Nomenclature (2013). Basel: S. Karger and Cytogenetic and Genome Research; 2013.
- [25] Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: *JAK2*, *MPL*, *TET2*, *ASXL1*, *CBL*, *IDH* and *IKZF1*. *Leukemia* 2010;24:1128–38.